23 March 2021 — The Defender
In an interview with Tucker Carlson, Dr. Hooman Noorchashm says we’re taking the COVID pandemic problem, where a half-percent of the population is susceptible to dying, and compounding it by vaccinating people who are already infected.
Dr. Hooman Noorchashm wants people to know that he’s a staunch supporter of the new COVID-19 vaccines, but with one very important warning: People who have already been infected could be at risk of serious injury, including death.
In the interview below on Tuesday’s Tucker Carlson Tonight show, Noorchashm said:
“I think it’s a dramatic error on part of public health officials to try to put this vaccine into a one-size-fits-all paradigm … We’re going to take this problem we have with the COVID-19 pandemic, where a half-percent of the population is susceptible to dying, and compound it by causing totally avoidable harm by vaccinating people who are already infected … the signal is deafening, the people who are having complications or adverse events are the people who have recently or are currently or previously infected [with COVID]. I don’t think we can ignore this.”
As The Defender reported earlier this month, Noorchashm believes that a #ScreenB4Vaccine campaign could save millions from vaccine injuries. The cardiothoracic surgeon and patient safety advocate has been speaking out about the need to screen people before administering the COVID vaccines ever since his initial plea to Pfizer and the U.S. Food and Drug Administration (FDA) failed to generate a satisfactory response.
In a Jan. 26 letter to FDA officials, Noorchashm warned that if viral antigens are present in the tissues of subjects who undergo vaccination, the antigen-specific immune response triggered by the vaccine will target those tissues and cause tissue inflammation and damage.
Noorchashm told regulators that “at the very minimum” Pfizer and Moderna should “institute clear recommendations to clinicians that they delay immunization in any recently convalescent patients, as well as, any known symptomatic or asymptomatic carriers — and to actively screen as many patients with high cardiovascular risk as is reasonably possible, in order to detect the presence of SARS-CoV-2, prior to vaccinating them.”
The Defender reached out to Noorchashm today, after his interview with Carlson, with a request to explain his concerns in more detail.
In an email he wrote:
“Viral antigens persist in the tissues of the naturally infected for months. When the vaccine is used too early after a natural infection, or worse during an active infection, the vaccine force activates a powerful immune response that attacks the tissues where the natural viral antigens are persisting. This, I suggest, is the cause of the high level of adverse events and, likely deaths, we are seeing in the recently infected following vaccination.”
The solution, Noorchashm said, is pre-screening before vaccination.
He told us:
“The pre-vaccine screening campaign I’d like to start is #ScreenB4Vaccine. This consists of a PCR or Rapid Antigen test to determine if there is an active infection AND an IgG antibody test that would allow determination of a past infection. If either of these tests are positive, vaccination ought to be delayed for a minimum of 3 – 6 months. If at that time IgG levels are waning, it is reasonable to consider getting a vaccine shot. But even then, blood IgG levels should guide whether or not a person gets vaccinated.”
Noorchashm told us that anyone who has had a natural symptomatic or asymptomatic COVID-19 infection is highly likely to have developed immunity. “This immunity can be measured by assessing for the presence of IgG antibodies specific for the SARS-CoV-2 viral antigens,” he said. “So any persons who are found to be positive for IgG can assume a prior infection. The IgG antibody assays are either qualitative (i.e., a YES or NO answer) or quantitative (i.e., the amount of blood IgG is measured).”
The initial screening can be qualitative, Noorchashm said. “If a person is found to be positive for IgG, then a quantitative titer can be drawn,” he explained. “This can then serve as a baseline metric upon which vaccination decisions are based. When IgG levels start to wane is when a booster vaccination could be considered.”
Children’s Health Defense supports Noorchashm’s efforts to require screening for SARS-CoV-2 antibodies before receiving any of the three COVID vaccines being administered in the U.S., but also believes the vaccines can cause other types of injuries.
According to Lyn Redwood, president emerita of Children’s Health Defense, tens of thousands of adverse events have been reported to the Vaccine Adverse Event Reporting System (VAERS) since mid-December when the first COVID vaccine was administered. “These reports deserve the full attention of our regulators,” Redwood said. “Unfortunately, the lack of scrutiny and post-mortem examinations make it impossible to determine when injuries and deaths are caused by the vaccines.”
Noorchashm told Carlson that he’s been wrongly accused of stoking vaccine hesitancy, when just the opposite is true — if public health officials want people to trust the vaccines, they need to do everything possible to avoid creating situations where the vaccines can actually cause harm.
“People aren’t stupid,” Noorchashm said. “If you explain how the vaccine works, and give them the information on how to keep themselves safe,” that is how you build trust.
Watch Noorchashm’s interview with Tucker Carlson here: